Racial differences in the risk of second primary bladder cancer following radiation therapy among localized prostate cancer patients.
Black or African American
/ statistics & numerical data
Health Status Disparities
Humans
Louisiana
/ epidemiology
Male
Neoplasms, Radiation-Induced
/ ethnology
Neoplasms, Second Primary
/ ethnology
Prostatic Neoplasms
/ ethnology
Race Factors
Risk Factors
Urinary Bladder Neoplasms
/ ethnology
White People
/ statistics & numerical data
Prostate cancer
Racial difference
Radiation therapy
Second primary bladder cancer
Journal
Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
21
12
2020
revised:
03
06
2021
accepted:
07
06
2021
pubmed:
20
6
2021
medline:
28
8
2021
entrez:
19
6
2021
Statut:
ppublish
Résumé
To investigate the race-specific second primary bladder cancer (SPBC) risk following prostatic irradiation. Louisiana residents who were diagnosed with localized prostate cancer (PCa) in 1996-2013 and received surgery or radiation were included. Patients were followed until SPBC diagnosis, death, or Dec. 2018. The exposure variable was type of treatment (radiation only vs. surgery only). The outcome was time from PCa diagnosis to SPBC diagnosis, stratified by race. Fine and Gray's competing risk model was applied with death as a competing event and adjustment of sociodemographic and tumor characteristics. We used 5 years and 10 years as lag time in the analyses. A total of 26,277 PCa patients with a median follow-up of 10.7 years were analyzed, including 18,598 white and 7679 black patients. About 42.9 % of whites and 45.7 % of blacks received radiation. SPBC counted for 1.84 % in the radiation group and 0.90 % in the surgery group among white patients and for 0.91 % and 0.58 %, respectively, among black patients. The adjusted subdistribution hazard ratio of SPBC was 1.80 (95 % CI: 1.30-2.48) for radiation recipients compared to surgery recipients among white patients; 1.93 (95 % CI: 1.36-2.74) if restricted to external beam radiation therapy (EBRT). The SPBC risk was not significantly different between irradiated and surgically treated among blacks. The SPBC risk is almost two-fold among white irradiated PCa patients compared to their counterparts treated surgically. Our findings highlight the need for enhanced surveillance for white PCa survivors receiving radiotherapy, especially those received EBRT.
Identifiants
pubmed: 34146916
pii: S1877-7821(21)00084-9
doi: 10.1016/j.canep.2021.101967
pmc: PMC8357014
mid: NIHMS1716144
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
101967Subventions
Organisme : NCI NIH HHS
ID : HHSN261201800007C
Pays : United States
Organisme : NIMHD NIH HHS
ID : R15 MD012387
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000057I
Pays : United States
Organisme : CDC HHS
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Radiother Oncol. 2014 Feb;110(2):213-28
pubmed: 24485765
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Urology. 2009 Oct;74(4):866-71
pubmed: 19628258
Urol Oncol. 2013 Nov;31(8):1628-34
pubmed: 22575239
N Engl J Med. 2013 Jan 31;368(5):436-45
pubmed: 23363497
J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67
pubmed: 15367568
Hum Mol Genet. 2011 Nov 1;20(21):4282-9
pubmed: 21824976
JAMA. 2017 Mar 21;317(11):1141-1150
pubmed: 28324092
Cancer Manag Res. 2019 Jan 10;11:587-598
pubmed: 30666156
J Clin Oncol. 2011 Dec 1;29(34):4510-5
pubmed: 22025166
J Urol. 2006 Dec;176(6 Pt 1):2474-81; discussion 2481
pubmed: 17085133
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):295-302
pubmed: 25636756
Radiother Oncol. 2011 Jan;98(1):81-6
pubmed: 20951450
World J Urol. 2019 Jan;37(1):3-13
pubmed: 30105454
BMJ. 2016 Mar 02;352:i851
pubmed: 26936410
J Urol. 2008 Nov;180(5):2005-9; discussion 2009-10
pubmed: 18801517
Cancer. 2014 Sep 1;120(17):2735-41
pubmed: 24842808
Lancet Oncol. 2011 Apr;12(4):353-60
pubmed: 21454129
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):251-5
pubmed: 9607337
Int J Clin Oncol. 2019 Aug;24(8):957-965
pubmed: 30903422
JAMA Netw Open. 2019 Jun 5;2(6):e195536
pubmed: 31173129
Eur Urol. 2019 Feb;75(2):319-328
pubmed: 30293908
Br J Radiol. 2019 Jan;92(1093):20180390
pubmed: 30102558
BJU Int. 2012 Dec;110(11):1696-701
pubmed: 22889401
Acta Oncol. 2019 Jun;58(6):838-844
pubmed: 30905229
Nat Genet. 2010 Nov;42(11):978-84
pubmed: 20972438
Cancer. 2000 Jan 15;88(2):398-406
pubmed: 10640974
J Urol. 2008 May;179(5 Suppl):S2-5
pubmed: 18405742
Hum Mol Genet. 2014 Mar 1;23(5):1387-98
pubmed: 24163127
Nat Genet. 2009 Sep;41(9):991-5
pubmed: 19648920
J Urol. 2006 Sep;176(3):927-33; discussion 933-4
pubmed: 16890657
Radiother Oncol. 2002 Dec;65(3):145-51
pubmed: 12464442
Sci Rep. 2018 Aug 21;8(1):12521
pubmed: 30131523
Nat Genet. 2010 May;42(5):415-9
pubmed: 20348956
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Nat Genet. 2008 Nov;40(11):1307-12
pubmed: 18794855
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):342-8
pubmed: 20117287
Cancer. 2006 Sep 1;107(5):991-8
pubmed: 16878323
Hum Mol Genet. 2011 Nov 1;20(21):4268-81
pubmed: 21750109
Int J Cancer. 2008 Sep 1;123(5):1141-5
pubmed: 18546265
BMC Cancer. 2020 Feb 3;20(1):90
pubmed: 32013912
Radiat Oncol. 2017 Jan 3;12(1):2
pubmed: 28049538
J Urol. 2019 Jan;201(1):120-128
pubmed: 30059685
Hum Mol Genet. 2014 Oct 15;23(20):5545-57
pubmed: 24861552
J Urol. 2008 May;179(5 Suppl):S7-S11
pubmed: 18405759
J Urol. 2007 Mar;177(3):883-7; discussion 887-8
pubmed: 17296367
Cancer. 2007 Jan 1;109(1):164; author reply 165
pubmed: 17123271
J Urol. 1998 Mar;159(3):946-9
pubmed: 9474189
Cancer. 1997 Apr 15;79(8):1600-4
pubmed: 9118045